COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

ENB and Photodynamic Therapy in the Treatment for Early Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03211078
Recruitment Status : Unknown
Verified July 2017 by National Taiwan University Hospital.
Recruitment status was:  Recruiting
First Posted : July 7, 2017
Last Update Posted : July 12, 2017
Information provided by (Responsible Party):
National Taiwan University Hospital

Brief Summary:
With the increased incidence of lung cancer and prevalence of low dose CT screening, treating of early lung cancer has becoming an important issue in the clinical practice of thoracic oncology. In this clinical study, the investigators will evaluate whether superDimension (superD) ENB (Electromagnetic navigation bronchoscopy) in combination with interstitial photodynamic therapy can provide the chance of tumor eradication.

Condition or disease Intervention/treatment Phase
Lung Cancer Procedure: super-D ENB guided-PDT Not Applicable

Detailed Description:

Lung cancer is the one the major cause of cancer death all over the world especially in Asia. The prevalence of low dose CT screening has made more patients of lung cancer treated in the early stage. The treatment of choice for of early lung cancer is surgical resection. However, several difficulties exist in surgery for treating early lung cancer. eg. Some presenting as multi-focal lesions, which cannot be completely eradicated by surgical resection.

Electromagnetic navigation bronchoscopy (ENB)(superDimension™ Navigation System, super-D ENB) is a novel technique, which uses an image guided localization system to direct steerable bronchoscopic tools to predetermined points within the bronchial tree. This technology allows improved access to peripheral lesions in particular.

Photodynamic therapy (PDT) has been adopted an effective treatment option for the central located lung cancer by using photosensitizer which is focally retained in the tumor leading to tumor-specific abrasion by irradiating with a certain wave-length of light. The most frequently used and commercially available photosensitizer for lung cancer is PDT with Photofrin under 623 nm red light irradiation. For the peripheral lung cancer which cannot be approached by bronchoscopy, interstitial PDT with the aids of CT guided catheter implantation has been adopted. However, there are potential disadvantages of such approach including 1) bleeding or hemothorax during CT-guided catheter implantation; 2) dislodging of the catheter after lung collapse in the procedure; 3) unable to treat other lesion after pneumothorax.

In the current proposal, the investigators use ENB in combination with PDT to handle to test the feasibility of super-D ENB guided-PDT to treat small lung cancer which cannot be eradicated through surgical resection.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Application of Electro-magnetic Navigation Bronchoscopy (ENB) and Photodynamic Therapy in the Treatment for Early Lung Cancer
Actual Study Start Date : October 14, 2016
Estimated Primary Completion Date : September 1, 2017
Estimated Study Completion Date : September 15, 2017

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: super-D ENB guided-PDT
To test the feasibility of super-D ENB guided-PDT to treat small lung cancer which cannot be eradicated through surgical resection.
Procedure: super-D ENB guided-PDT
PDT with super-D EBN localization will be given for treating the target lung lesion. Intrvenous photofrin (2mg/kg) will be given 48 hours before intervention. After localization of the tumor by ENB, a 630nm of light will be give for the lesion with the dosage of 2oo J/cm. Intravenous general anesthesia and endobronchial intubation will be performed under the whole procedure.

Primary Outcome Measures :
  1. Disease-free survival [ Time Frame: 5 years ]
    The time interval between enrollment and the earliest onset of any of the following events,: tumor local recurrence , distant metastasis, and mortality

Secondary Outcome Measures :
  1. post-operative complication [ Time Frame: 3 month ]
    defined as any deviation from the normal postoperative course

  2. post-operative pulmonary function [ Time Frame: 6, 12, and 24 months ]
    the pulmonary function at 6, 12, and 24 months post-operation

  3. overall survival [ Time Frame: 5 years ]
    The time interval between enrollment and death

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Multiple small lung cancer which cannot be completely removed by surgical resection.
  2. Patient with small early lung cancer with diameter less than 1 cm and with high surgical risk precluding surgery.
  3. Patient with small early lung cancer with diameter less than 1 cm but unwilling to receive surgical intervention.
  4. Age above 20 years old and who can do the bronchoscopy test

Exclusion Criteria:

1. Bleeding tendency. 2 .Poor cardiopulmonary function with intolerance to bronchoscopy examination.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03211078

Layout table for location contacts
Contact: Jang-Ming Lee, MD. PhD.
Contact: Peiwen Yang, PhD.

Layout table for location information
National Taiwan University Hospital Recruiting
Taipei, Zhongzheng Dist., Taiwan, 100
Contact: Jang-Ming Lee    886-972651439   
Sponsors and Collaborators
National Taiwan University Hospital
Layout table for investigator information
Principal Investigator: Jang-Ming Lee, MD. PhD. National Taiwan University Hospital
Layout table for additonal information
Responsible Party: National Taiwan University Hospital Identifier: NCT03211078    
Other Study ID Numbers: 201407063DINB
First Posted: July 7, 2017    Key Record Dates
Last Update Posted: July 12, 2017
Last Verified: July 2017

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by National Taiwan University Hospital:
Early lung cancer
Photodynamic therapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases